$JBIO
Jade Biosciences, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$16.94
▼-1.17%-$0.200
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateJade Biosciences, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is JBIO down today? It is at $16.94 (-1.17%), and our scanner flagged it 57 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment JBIO spikes, and full due diligence on JBIO — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $JBIO 57 times in the last 30 days. Create a free account to track $JBIO, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on JBIO from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for JBIO today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Frohlich Tom Officer | Acquired (grant/award) | +79K 0.1% of company | added 100% | 86K | n/a | Feb 12, 26 |
King Andrew James Officer | Acquired (grant/award) | +41K 0.06% of company | added 12% | 386K | n/a | Feb 12, 26 |
Balta Elizabeth Officer | Acquired (grant/award) | +28K 0.04% of company | n/a | 28K | n/a | Feb 12, 26 |
Dahms Bradford D. Officer | Acquired (grant/award) | +38K 0.06% of company | n/a | 38K | n/a | Feb 12, 26 |
Fairmount Funds Management Llc Director | Acquired (grant/award) | +1.33M 2.1% of company | added 41% | 4.55M | $12.2M at $9.14 | Oct 6, 25 |
Frohlich Tom Officer | Bought (open market) | +6K | n/a | 6K | $44K at $7.40 | May 16, 25 |
Ra Capital Management, L.P. Beneficial Owner (10%) | Acquired (grant/award) | +1.06M 1.7% of company | added 100% | 1.32M | n/a | Apr 28, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on JBIO from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for JBIO today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
JBIO last traded at $16.94, down 1.17% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Jade Biosciences, Inc. Common Stock (JBIO) is next expected to report earnings on Thursday, November 12, 2026, about 53 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The JBIO Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged JBIO 57 times in the last 30 days.
JBIO (Jade Biosciences, Inc. Common Stock) trades on XNAS, with a market cap of about $1.08B in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge JBIO for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$JBIO discussion
Sign in to ask a question or join the discussion.